Skip to content

SLF2 and SMC5 dysfunction drives HSC aging and predisposes to MDS, defining a new inherited bone marrow failure syndrome.

Aug 2026 · Leukemia · 1 citation · 62 references
Medicine

TL;DR

It is demonstrated that SLF2 and SMC5 dysfunction drives premature HSC aging, bone marrow failure, and predisposition to MDS, revealing Atelis Syndrome as a previously unrecognized IBMFS.

View source

Similar papers

Review Open access Aug 2026

Rare inherited bone marrow failure syndromes with cancer predisposition associated with SRP72, SH2B3, MYSM1 and CBL variants: a literature review and case series

The findings highlight the importance of early molecular genetic testing in children with persistent hematopoietic abnormalities, along with regular cytogenetic surveillance and timely referral of high-risk patients for HSCT.

M. S. Vasilyeva, A. Pavlova, D. Fedorova et al. · 0 citations
Open access Aug 2026

SRSF2 mutations contribute to bone marrow immune microenvironment alterations

It is suggested that the Srsf2 P95H/WT mutation contributes to the altered hematopoietic lineages composition and immune-related cellular states in BM, providing insights into its potential involvement in early-stage MDS and CMML progression.

Changrui Tao, Wei Li, Yu Jiang et al. · 0 citations
Case report Aug 2026

Bone Marrow Failure Syndromes: Clinical and Genetic Characterization in TERT-associated Dyskeratosis Congenita.

The clinical and genetic spectrum of TERT-associated DC is expanded and the critical role of genomic diagnostics and telomere assessment in BMFs is illustrated to illustrate the critical role of genomic diagnostics and telomere assessment in telomere biology disorders.

I. Somekh, A. Mandola, Shirly Frizinsky et al. · 0 citations
Jul 2026

KRAS G12D Blocks Erythroid Differentiation and Promotes Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies 2251571

Genotyping of Transcriptomes is used to elucidate specific KRASG12D-driven pathways in preleukemic Clonal Hematopoiesis and 3 Acute Myeloid Leukemia patient samples and identify a novel quiescent CD83+ KRASG12D progenitor population in AML and demonstrate the therapeutic potential of MRTX1133 in vivo.

Leah Kravets, Ritesh Agarwal, Srinivas Aluri et al. · 0 citations
Open access Sep 2026

Tet2 deficiency drives age-related heterogeneous progression of myeloid neoplasms through epigenetic-immune microenvironment imbalance

A hematopoietic specific Tet2 conditional knockout mouse model recapitulates core clinical features of elderly Tet2-mutated myeloid neoplasms and provides a preclinical platform for mechanistic investigation and the development of epigenetic and immune-targeted precision therapies.

Yan-Xia Chen, Li Yu, Rui Yang et al. · 0 citations
Open access Jul 2026

Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans

Treatment with senescence-targeting therapy improves BM hematopoietic stem and progenitor cells in vivo in mice and ex vivo in cells from individuals with SCD and could represent a possible strategy to improve HSPC health, promote manufacture of high quality bespoke clinical products, and potentially enhance the safety...

Aditya Barve, Preeti Dabas, Adam B. Cornwell et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.